12-5888-41
antibody from Invitrogen Antibodies
Targeting: PDCD1LG2
B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2
Antibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-5888-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD273 (B7-DC) Monoclonal Antibody (MIH18), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The MIH18 monoclonal antibody reacts with human B7-DC, also known as PD-L2. B7-DC, a recently identified member of the B7 family, has a predicted molecular weight of approximately 25 kDa and belongs to the Ig superfamily. B7-DC is primarily expressed by subpopulations of dendritic cells and monocytes/macrophages. Although B7-DC has structural and sequence similarities to the B7 family, it does not bind CD28/CTLA-4, rather it is a ligand for PD-1. The interactions between PD-1 and B7-DC/PD-L2 have been reported to be involved in costimulation or suppression of T cell proliferation depending on state of cellular activation. MIH18 is a useful tool for studies to elucidate the exact function of B7-DC/PD-L2 in APC/T cell interaction and to characterize the expression pattern of this molecule in humans. MIH18 is a blocking antibody. Applications Reported: The MIH18 antibody has been reported for use in flow cytometric analysis. Applications Tested: This MIH18 antibody has been pre-titrated and tested by flow cytometric analysis of mature dendritic cells and normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- MIH18
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Brugia malayi microfilariae induce a regulatory monocyte/macrophage phenotype that suppresses innate and adaptive immune responses.
HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.
Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma.
Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
TLR-mediated induction of negative regulatory ligands on dendritic cells.
No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.
Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W
Journal of hematology & oncology 2018 Feb 6;11(1):16
Journal of hematology & oncology 2018 Feb 6;11(1):16
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M
Oncotarget 2018 Apr 10;9(27):19177-19191
Oncotarget 2018 Apr 10;9(27):19177-19191
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, Klose D, Amoury M, Woitok M, Jost E, Brümmendorf TH, Fendel R, Fischer R, Stein C, Thepen T, Barth S
Oncotarget 2016 Oct 11;7(41):67166-67174
Oncotarget 2016 Oct 11;7(41):67166-67174
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.
Demoulin SA, Somja J, Duray A, Guénin S, Roncarati P, Delvenne PO, Herfs MF, Hubert PM
Oncoimmunology 2015 Jun;4(6):e1008334
Oncoimmunology 2015 Jun;4(6):e1008334
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG
Prostate cancer and prostatic diseases 2015 Dec;18(4):325-32
Prostate cancer and prostatic diseases 2015 Dec;18(4):325-32
Brugia malayi microfilariae induce a regulatory monocyte/macrophage phenotype that suppresses innate and adaptive immune responses.
O'Regan NL, Steinfelder S, Venugopal G, Rao GB, Lucius R, Srikantam A, Hartmann S
PLoS neglected tropical diseases 2014 Oct;8(10):e3206
PLoS neglected tropical diseases 2014 Oct;8(10):e3206
HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.
Planès R, BenMohamed L, Leghmari K, Delobel P, Izopet J, Bahraoui E
Journal of virology 2014 Jun;88(12):6672-89
Journal of virology 2014 Jun;88(12):6672-89
Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.
Kim YJ, Park SJ, Broxmeyer HE
Journal of immunology (Baltimore, Md. : 1950) 2011 Sep 1;187(5):2291-301
Journal of immunology (Baltimore, Md. : 1950) 2011 Sep 1;187(5):2291-301
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jul 1;17(13):4232-44
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jul 1;17(13):4232-44
Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma.
Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT, Chang Y
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Oct;23(10):1393-403
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Oct;23(10):1393-403
Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.
Cavaleiro R, Baptista AP, Soares RS, Tendeiro R, Foxall RB, Gomes P, Victorino RM, Sousa AE
PLoS pathogens 2009 Nov;5(11):e1000667
PLoS pathogens 2009 Nov;5(11):e1000667
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM
Journal of immunology (Baltimore, Md. : 1950) 2009 May 1;182(9):5240-9
Journal of immunology (Baltimore, Md. : 1950) 2009 May 1;182(9):5240-9
TLR-mediated induction of negative regulatory ligands on dendritic cells.
Gröschel S, Piggott KD, Vaglio A, Ma-Krupa W, Singh K, Goronzy JJ, Weyand CM
Journal of molecular medicine (Berlin, Germany) 2008 Apr;86(4):443-55
Journal of molecular medicine (Berlin, Germany) 2008 Apr;86(4):443-55
No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.
Pfistershammer K, Klauser C, Pickl WF, Stöckl J, Leitner J, Zlabinger G, Majdic O, Steinberger P
European journal of immunology 2006 May;36(5):1104-13
European journal of immunology 2006 May;36(5):1104-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of human monocyte-derived dendritic cells with Anti-Human CD11c APC (Product # 17-0116-42) and Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (left) or Anti-Human CD273 (B7-DC) PE (right). Cells in the large scatter population were used for analysis.
- Conjugate
- Yellow dye